skip to main content

Cevimeline Sjogren Alternative — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateConnective Tissue DiseaseCevimeline Sjogren AlternativeSCE Rheumatology

A 50-year-old woman with anti-Ro-positive primary Sjögren disease has persistent xerostomia, difficulty eating dry food and two new carious lesions in the past year. She has no extraglandular disease activity (ESSDAI 0) and normal renal and haematological indices. Oral pilocarpine was stopped after drenching sweats and diarrhoea persisted despite slow dose titration and reduction. Which is the most appropriate next step in UK practice?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Optimise saliva substitutes, salivary stimulation and preventive dental care

Explanation lettering: B = shown as A · E = shown as B · D = shown as C · A = shown as D · C = shown as E

D is correct. The BSR Sjögren disease guideline structures sicca care around conserving, replacing and stimulating secretions and preventing damage: saliva substitutes and gels, mechanical/gustatory stimulation such as sugar-free gum, fluoride and regular dental review to prevent caries. Pilocarpine is the systemic secretagogue used in the UK; when cholinergic effects such as sweating and diarrhoea persist despite titration, symptomatic replacement and caries prevention are optimised. E is the key trap: cevimeline is a relatively M1/M3-selective muscarinic agonist licensed in the USA and Japan, but it has no UK marketing authorisation and comparative data do not prove better tolerability, so it is not a routine UK option. Rituximab (C) has not shown reliable benefit for sicca alone and, with IVIg (B), is reserved for active systemic disease. A is wrong because effective symptomatic and dental-preventive measures exist.

Reference: Price EJ, Benjamin S, Bombardieri M, et al. British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease — management of dry mouth (conserve, replace, stimulate secretions; prevent damage). Rheumatology 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013823/